Page last updated: 2024-08-24

aristeromycin and Prostatic Neoplasms

aristeromycin has been researched along with Prostatic Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kawamoto, T; Tanaka, Y; Uchiyama, N	1

Other Studies

1 other study(ies) available for aristeromycin and Prostatic Neoplasms

Article	Year
Aristeromycin and DZNeP cause growth inhibition of prostate cancer via induction of mir-26a. European journal of pharmacology, 2017, Oct-05, Volume: 812 Topics: Adenosine; Adenosylhomocysteinase; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enhancer of Zeste Homolog 2 Protein; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; MicroRNAs; Prostatic Neoplasms; RNA, Small Interfering; Transcriptional Activation	2017

Article

Year

Aristeromycin and DZNeP cause growth inhibition of prostate cancer via induction of mir-26a.

European journal of pharmacology, 2017, Oct-05, Volume: 812

Topics: Adenosine; Adenosylhomocysteinase; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enhancer of Zeste Homolog 2 Protein; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; MicroRNAs; Prostatic Neoplasms; RNA, Small Interfering; Transcriptional Activation

2017